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Aim: Diabetes mellitus (DM) is associated with brain atrophy and vascular brain lesions. Cardiovascular dis-
ease is a key determinant in this association. We assessed whether DM increased the rate of progression of
brain atrophy, vascular brain lesions, and cognitive decline in patients with symptomatic atherosclerotic dis-
ease.
Methods: In 663 patients (58 ± 10 years) from the SMART-MR study (n = 89 with DM), 1.5 T MRI and neu-
ropsychological examination were performed at baseline and after 3.9 ± 0.4 years follow-up.
Results: Repeated measures ANCOVA (adjusted for age, sex, and vascular risk factors) showed that patients with
DM had smaller total brain volume (mean differences as percentage of intracranial volume (ICV) [95% CI]:
−1.36% [−1.81; −0.91]), smaller gray matter volume (−1.23% [−1.85; −0.61]), larger ventricular vol-
ume (0.32% [0.14; 0.49]), and larger white matter lesion volume (0.31% [0.09; 0.53]) than patients without
DM. Patients with DMhad accelerated increase in ventricular volume over time comparedwith patients without
DM (mean differences ventricular volume as percentage of ICV: 0.32% [0.25; 0.39] vs. 0.17% [0.15; 0.19];
p-interaction DM × time b 0.01). Poisson regression showed that patients with DMhad an increased risk for in-
cident brain infarcts (relative risk [95% CI]: 1.62 [1.04; 2.53]). Patients with and without DM had similar perfor-
mance on cognition.
Conclusions: DM on top of existing symptomatic atherosclerotic disease is associated with increased brain atro-
phy and vascular brain lesion load that proceed at a slightly higher rate than in patients without DM.© 2013 Elsevier B.V. All rights reserved.1. Introduction
Type 2 diabetes mellitus (DM2) is associated with an increased risk
of dementia [1,2]. Moreover, several cross-sectional studies have indi-
cated that non-demented patients with DM2 haveworse cognitive per-
formance compared to controls [3,4]. However, it is less clear at which
rate cognition declines in non-demented patients with DM2 [5]. Some
longitudinal studies have found a decline in cognitive performance
that clearly exceeded the rate of normal aging [6–8], but this could
not be conﬁrmed by others [9,10].
The cognitive impairments of patients with DM2 are related to
changes in brain structures, as can be seen on magnetic resonanceiences and Primary Care, UMC
ht, The Netherlands. Tel.: +31
erlings).
l rights reserved.imaging (MRI). Patients with DM2 have more vascular brain lesions,
likewhitematter lesions (WMLs) or infarcts, andmore cortical and sub-
cortical atrophy than patients without DM2 [3,11,12]. Recently, these
MRI abnormalities have also been assessed longitudinally. In a prospec-
tive study where patients with DM2 were compared with controls, an
accelerated progression of subcortical atrophy, reﬂected by an increase
in ventricular volume,was found in patientswith DM2 [13]. Other stud-
ies have also found accelerated progression of total brain atrophy in pa-
tients with DM when compared with controls [14,15].
Vascular risk factors and vascular disease are important determi-
nants for brain atrophy and vascular brain lesions [16,17]. In patients
with DM2, symptomatic atherosclerotic disease was associated with
brain MRI abnormalities [18]. Moreover, even among patients with
symptomatic atherosclerotic disease, presence of DM was associated
with relatively more brain atrophy and more vascular brain lesions in
a previous cross-sectional study from our group [19]. However, the as-
sociation between DM, vascular disease, and progression of brain MRI
changes over time has not yet been studied in detail. In the current
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progression of brain MRI abnormalities and declines in cognition in a
population of patients with symptomatic atherosclerotic disease.
2. Methods
2.1. SMART-MR study
Data were used from the SecondManifestations of ARTerial disease—
Magnetic Resonance (SMART-MR) study, a prospective cohort study
aimed to investigate brain changes on MRI in independently living pa-
tients with symptomatic atherosclerotic disease [16,20]. Between May
2001 and December 2005, all patients newly referred to the University
Medical Center Utrecht withmanifest coronary artery disease, cerebro-
vascular disease, peripheral arterial disease or an abdominal aortic an-
eurysm, and without MR contraindications were invited to participate.
During a one-day visit, an MRI of the brain was performed, in addition
to a physical examination, ultrasonography of the carotid arteries, and
blood and urine sampling. Risk factors, medical history, and functioning
were assessed with questionnaires. Neuropsychological assessment was
introduced in the SMART-MR study in January 2003 and was performed
on the same day as the MRI and other investigations. Between January
2006 and May 2009, all participants still alive were invited for
follow-up measurements, including MRI of the brain and neuropsycho-
logical assessment. The SMART-MR study was approved by the ethics
committee of our institution andwritten informed consentwas obtained
from all participants.
2.2. Diabetes mellitus
Diabetes mellitus (DM) at baseline was deﬁned as a known histo-
ry of DM, self-reported or registered glucose-lowering therapy, or
glucose ≥11.1 mmol/L. Patients not meeting these criteria, but with a
fasting plasma glucose level≥7.0 mmol/L at baseline, were considered
to have DM at baseline if they received treatment with glucose-
lowering agents within 1 year after baseline [21].
2.3. MRI protocol
MRI investigationswere performedon a 1.5 Teslawhole-body system
(Gyroscan ACS-NT, Philips Medical Systems, Best, The Netherlands). The
protocol consisted of transversal T1-weighted gradient-echo (repetition
time (TR)/echo time (TE): 235/2 ms), transversal T2-weighted turbo
spin-echo (TR/TE: 2200/11 ms and 2200/100 ms; turbo factor 12),
ﬂuid-attenuated inversion recovery (FLAIR) (TR/TE/inversion time
(TI): 6000/100/2000 ms), and transversal inversion recovery (IR)
(TR/TE/TI: 2900/22/410 ms) sequences (ﬁeld of view 230 × 230 mm;
matrix size, 180 × 256; slice thickness, 4 mm; no slice gap; 38 slices).
2.4. Brain segmentation
We used the T1-weighted gradient-echo, IR sequence and FLAIR se-
quence for brain segmentation. The probabilistic segmentation technique
has been described elsewhere [22,23]. The segmentation program distin-
guishes cortical graymatter, whitematter, sulcal and ventricular cerebro-
spinal ﬂuid (CSF), and WMLs. The automatic segmentation was visually
checked for presence of infarcts and adapted if necessary to make a
distinction between WMLs and infarct volumes. Total brain volume was
calculated by summing the volumes of gray and white matter and, if
present, the volumes of WMLs and infarcts. All volumes cranial to the
foramen magnum were included. As a result, the total brain volume
includes the cerebrum, brainstem and cerebellum. Total intracranial
volume (ICV) was calculated by summing the total brain volume and
the volumes of sulcal and ventricular CSF.2.5. Brain infarcts and white matter lesions
At baseline and follow-up, infarcts were rated visually by an
investigator and neuroradiologist, blinded to clinical characteristics and
were re-evaluated in a consensus meeting. Infarcts were deﬁned as
focal hyperintensities on T2-weighted images of N3 mm in diameter.
These T2 hyperintensities, when located in the white matter, also had
to be hypointense on T1-weighted and FLAIR images to distinguish
them from WMLs. Patients with an increase in number of infarcts be-
tween baseline and follow-up were considered to have incident infarcts.
Volumes ofWMLs obtainedwith the segmentation program consisted of
periventricular and deep lesions and were summed to obtain the total
volume of WMLs. WML volumes were normalized for ICV and natural
log transformed.
2.6. Brain volumes
All brain volumes (total brain volume, cortical gray matter volume,
ventricular volume) were expressed relative to ICV. Total brain volume
was used as an indicator of global brain atrophy, cortical gray matter
volume as an indicator of cortical brain atrophy, and ventricular volume
as an indicator of subcortical brain atrophy.
2.7. Neuropsychological assessment
At baseline and follow-up, memory and executive functioning were
assessed with neuropsychological tests, sensitive to mild impairments
as described earlier [24]. Composite z-scores for the domains memory
and executive functioning were calculated based on the total study
population. The composite score for memory included immediate and
delayed recall and the retention score of the 15-word learning test
(a modiﬁcation of the Rey Auditory Verbal Learning test), and the de-
layed recall of the Rey–Osterrieth Complex Figure test. The composite
score for executive function included the Visual Elevator test, the
Brixton Spatial Anticipation test and the Verbal Fluency test (letter
N for baseline and letter A for follow-up, 1 minute time frame). Compos-
ite z-scores were computed by converting raw scores to standardized
z-scores and averaging them of all subtests per domain. Before calculat-
ing z-scores, the scores of the Visual Elevator test and the Brixton Spatial
Anticipation test weremultiplied byminus one so that lower scores rep-
resented poorer performance. The composite z-scores at follow-upwere
calculated by using the means and standard deviations of the baseline
test scores. Premorbid intellectual functioning was estimated using the
Dutch version of the National Adult Reading Test (DART) [25]. Educa-
tional level was recorded and divided into eight categories, graded
from primary school to academic degree, according to the Dutch educa-
tional system.
2.8. Covariates
An overnight fasting venous blood sample was taken to determine
lipid levels. Hyperlipidemia (yes/no) was deﬁned as total cholesterol
N5.0 mmol/L, low-density lipoprotein cholesterol N3.2 mmol/L, or
self-reported use of lipid-lowering drugs. Height and weight were
measured without shoes and heavy clothing, and body mass index
(BMI) was calculated (kg/m2). Systolic and diastolic blood pressure
(mm Hg) were measured twice in supine position with a sphygmo-
manometer and averaged. Pack-years of smoking were calculated,
and alcohol intake was categorized into never, former and current.
2.9. Study sample
Of the 1309 patients at baseline, 19 had no MRI, 14 had no FLAIR
sequence and in 44 patients brain volume data were missing due to
motion or artifacts. As a result, baseline MRI data were available in
1232 patients. Of the 1232 patients, 718 patients participated in the
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n = 66 died). Of these 718 patients, 38 had no MRI, and in 17 pa-
tients brain volume data were missing due to motion or artifacts.
This resulted in 663 patients (89 patients (13%) with DM) with available
MRI data at baseline and follow-up. Since neuropsychological assessment
was introduced later in the study, data on neuropsychological testing
were available in 473 patients (59 patients (12%)with DM) both at base-
line and follow-up.
2.10. Data analysis
Baseline characteristics were calculated for the study sample of
663 patients, and for patients with and without DM. Between group
differences in characteristics were analyzed with independent t-tests,
Mann–Whitney U test for non-parametric data, and chi-square tests
for proportions. Associations between presence of DM and progression
of brain abnormalities and changes in cognition over time were ana-
lyzed with repeated-measures analyses of covariance (ANCOVA), in-
cluding the effect of group, time, and the time × group interaction.
The effect of group reﬂects the mean difference between patients with
DM and patients without DM; the effect of time reﬂects the mean
change in measures of brain volume (% ICV) or mean change in
z-score of cognition for the study sample during follow-up (n = 663
and n = 473 respectively); the time × group interaction reﬂected the
additional change over time attributable to DM status. p-Values b0.05
were considered statistically signiﬁcant.
For the association between presence of DM and incidence of
brain infarcts we used Poisson regression models with log-link func-
tion and robust standard errors to estimate relative risks (RR) and ac-
companying conﬁdence intervals (CI) rather than odds ratio which
overestimate the relative risk, particularly for outcomes that are com-
mon (N10%) [26,27]. A distinction between lacunar and cortical infarcts
was not made, because groups would become too small to gain enough
power for the analyses.
All abovementionedmodels were adjusted for age and sex (model 1;
for the association with cognitive decline educational level and DART-
score were also included in the model). In model 2 we additionally
adjusted for vascular risk factors (systolic and diastolic blood pressure,
BMI, hyperlipidemia, smoking and alcohol) and history of cerebrovascu-
lar disease. For the association between presence of DM and incidence of
brain infarcts we additionally adjusted for presence of brain infarcts at
baseline (model 3).
In secondary analyses, we excluded 42 patients who developed DM
during the follow-up period from the non-diabetic group and we re-
peated the analyses.Table 1
Baseline characteristics of the study sample.
Total (n = 663) Dia
Age (years) 57.5 ± 9.5 60.
Sex (% male) 81.3 79.
Educational level (1–7)a 3 (2–6) 3 (1
DART-scorea 82 (58–97) 81
Follow-up time (years) 3.9 ± 0.4 3.9
Vascular risk factors
BMI (kg/m2) 26.8 ± 3.5 27.
Systolic BP (mm Hg) 140 ± 20 143
Diastolic BP (mm Hg) 81 ± 10 81
Hyperlipidemia (% yes) 78% 78%
Smoking (pack years)a 20.2 (0–49) 22.
Alcohol intake (% current) 79% 66%
Vascular disease category
Coronary artery disease (%) 62% 61%
Cerebrovascular disease (%) 23% 30%
Peripheral arterial disease (%) 18% 24%
Abdominal aortic aneurysm (%) 6% 8%
Percentage of missing values before imputation: educational level (38%), DART-score (37%), B
a Median (10th–90th percentile).We used multiple imputation [28] (10 datasets) to address missing
values in the study sample, using the statistical programR (AreImpute).
Data were analyzed using IBM SPSS Statistics version 20.0 (IBM, New
York, NY, USA), by pooling the 10 imputed datasets.
3. Results
Mean [SD] age of the study population was 58 [10] years and the
majority was men (81%). Patients with DM were on average older
(61 [9] vs. 57 [9]), had a higher BMI (27.8 [3.8] vs. 26.6 [3.4]), systolic
blood pressure (143 [17] vs. 140 [20]) and more often a history of cere-
brovascular disease or cerebrovascular disease at inclusion (30% vs. 22%)
than patients without DM (Table 1). The follow-up assessment took
place at 3.9 [0.4] years after baseline in both groups.
3.1. Presence of DM and progression of brain MRI abnormalities
Results of the repeated measures ANCOVA on the association be-
tween DM and progression of brain MRI abnormalities are presented
in Table 2 and Fig. 1. Brain MRI abnormalities were more pronounced
in patients with DM than in patients without DM (Table 2). This was
represented by a smaller total brain volume (mean difference in brain
volume as percentage of ICV [95% CI] for patients with DM compared
with patients without DM: −1.36% [−1.81; −0.91]), a smaller gray
matter volume (−1.23% [−1.85;−0.61]), a larger ventricular volume
(0.32% [0.14; 0.49]), and a largerWML volume (0.31% [0.09; 0.53]). Fur-
thermore, brainMRI abnormalities progressed signiﬁcantly over time in
both groups (Table 2). Total brain volume and gray matter volume
decreased over time (mean change as percentage of ICV over the
follow-up period [95% CI] in total brain volume = −1.01% [−1.12;
−0.90] and in gray matter volume = −1.77% [−2.01; −1.52]),
and ventricular volume and WML volume increased over time for the
whole study sample (ventricular volume = 0.23% [0.20; 0.26] and
WML volume = 0.12% [0.05; 0.20]).
Patients with DM showed an accelerated increase in ventricular
volume over time relative to patients without DM (mean differences
in ventricular volume as percentage of ICV [95% CI]: 0.32% [0.26; 0.39] vs.
0.17% [0.15; 0.19]; p-value time × group interaction b 0.01). Total brain
volume, gray matter volume and WML volume showed no accelerated
changes in patients with DM (p-value time × group interaction N 0.05).
Additional adjustment for vascular risk factors and history of cerebrovas-
cular disease only slightly attenuated the results (Table 2).
There were 82 patients with incident brain infarcts (n = 19with DM
vs. n = 63withoutDM). The risk for incident brain infarctswas increased
in patients with DM relative to patients without DM (RR = 1.62, 95% CIbetes (n = 89) Non-diabetes (n = 574) p-Values
6 ± 9.3 57.0 ± 9.4 b0.01
8 81.5 0.69
–6) 4 (2–6) 0.14
(61–97) 82 (57–97) 0.98
± 0.4 3.9 ± 0.4 0.80
8 ± 3.4 26.6 ± 3.5 b0.01
± 17 140 ± 20 0.14
± 10 82 ± 11 0.35
78% 0.82
4 (0–55) 19.5 (0–47) 0.07
80% b0.01
62% 0.81
22% 0.14
18% 0.15
6% 0.39
MI (0.2%), hyperlipidemia (1.8%), alcohol (0.5%), smoking (0.3%), all other variables 0.0%.
Table 2
Differences in brain volumes between patients with and without diabetes and over time for the whole study group.
Model Mean differences between DM and non-DMa Mean change over timeb Time × group interaction p-Value
Total brain volume (% of ICV) 1 −1.36 (−1.81; −0.91) −1.01 (−1.12; −0.90) n.s.
2 −1.19 (−1.64; −0.75) −1.00 (−1.11; −0.88) n.s.
Gray matter volume (% of ICV) 1 −1.23 (−1.85; −0.61) −1.77 (−2.01; −1.52) n.s.
2 −1.07 (−1.69; −0.45) −1.75 (−2.00; −1.50) n.s.
Ventricular volume (% of ICV) 1 0.32 (0.14; 0.49) 0.23 (0.20; 0.26) b0.01
2 0.28 (0.11; 0.45) 0.23 (0.20; 0.26) b0.01
WML volumec 1 0.31 (0.09; 0.53) 0.12 (0.05; 0.20) n.s.
2 0.29 (0.07; 0.50) 0.14 (0.06; 0.22) n.s.
Data are brain volumes as percentage of ICV (95% conﬁdence interval)with repeated-measures analysis of covariance.Model 1 adjusted for age and sex, model 2 additionally adjusted for
BMI, alcohol, smoking, hyperlipidemia, systolic and diastolic blood pressure, and cerebrovascular disease. Percentage ofmissing values before imputation: graymatter fraction (17.5%), all
other variables (0.0%).
DM = diabetes mellitus; WML = white matter lesion; ICV = intracranial volume.
a Non-DM group is reference.
b For the whole study sample (n = 663).
c Log transformed WML volume.
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after additional adjustment for vascular risk factors and history of
cerebrovascular disease (model 2; RR = 1.45, 95% CI 0.92–2.29),
and presence of brain infarcts at baseline (model 3; RR = 1.30, 95%
CI 0.81–2.06; stratiﬁed for respectively presence or absence of in-
farcts at baseline RR = 1.26, 95% CI 0.71–2.23 and RR = 1.55, 95%
CI 0.73–3.31).3.2. Presence of DM and cognitive decline
Results of the repeatedmeasures ANCOVA of the analyses on the as-
sociation between DM and cognitive decline are presented in Table 3.
Patients with and without DM had similar performance on memory as
well as executive functioning (Table 3). After four years of follow-up,
memory performance and executive functioning did not decline for
the whole study sample. Decline in memory performance or executive80
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fraction; WML volume (ln) = log transformed white matter lesion volume.functioning was not accelerated in patients with DM compared to
those without DM (p-value time × group interaction N 0.05).
In secondary analyses, exclusion of patients who developed DM
during the follow-up period (n = 42) from the non-diabetic group
did not change the results (data not shown).4. Discussion
In a population of patients with symptomatic atherosclerotic dis-
ease, patients with DM had more brain atrophy and vascular brain le-
sions (WMLs and infarcts) than patients without DM. Brain atrophy
and vascular brain lesions progressed over four years in both groups,
and this progression was accelerated in patients with DM. Cognitive
performance did not differ between the groups and patients with DM
did not show accelerated cognitive decline compared with patients
without DM.BL FU
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d sex. BPF = brain parenchymal fraction; GMF = gray matter fraction; VF = ventricular
Table 3
Differences in cognitive domain z-scores for patients with and without diabetes and over time for the whole study group.
Model Mean differences between DM and non-DMa Mean change over timeb Time × group interaction p-Value
Memory performance (z-score) 1 −0.07 (−0.27; 0.13) 0.07 (−0.03; 0.17) n.s.
2 −0.03 (−0.23; 0.18) 0.07 (−0.03; 0.17) n.s.
Executive functioning (z-score) 1 −0.04 (−0.22; 0.15) −0.04 (−0.15; 0.07) n.s.
2 −0.01 (−0.19; 0.18) −0.04 (−0.15; 0.07) n.s.
Data are z-scores (95% conﬁdence interval) analyzed with repeated-measures analysis of covariance. Model 1 adjusted for age, sex, educational level and DART-score, model 2
additionally adjusted for BMI, alcohol, smoking, hyperlipidemia, systolic and diastolic blood pressure, and history of cerebrovascular disease.
DM = diabetes mellitus.
a Non-DM group is reference.
b For the whole study sample (n = 473).
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with results from previous cross-sectional studies, which consistently
report lower brain volumes and ventricular widening in patients with
DM [13,15,19,29]. Previous longitudinal studies have reported an ac-
celerated change in total brain volume [14] and ventricular volume
[13,30] in patients with DM relative to patients without DM. Overall,
the picture that emerges from previous and present observations, is
that brain volume changes in patients with DM progressing insidious-
ly over the years, at a rate that only slightly exceeds that of normal
aging.
For the association between DM and vascular brain lesions, the re-
sults of previous studies were inconsistent [12]. Some studies reported
larger WML volumes cross-sectionally [3,11] and an accelerated in-
crease in WML volume [31] in patients with DM over time, but this
was not conﬁrmed by others [13,14]. In the present study we found
an association between DM and larger WML volume, and also a slightly
accelerated increase in WML volume in patients with DM. In line with
previousﬁndings, the current longitudinal analyses showed a higher in-
cidence of brain infarcts in patientswithDM relative to patientswithout
DM, partly explained by presence of brain infarcts at baseline and a his-
tory of cerebrovascular disease [32].
Cognitive performance did not change signiﬁcantly over four years
of follow-up in the two groups. This could be caused by the fact that
the study included late middle-aged individuals with relatively intact
cognition. In contrast with previous ﬁndings [9,10], cognitive perfor-
mance was similar in patients with and without DM. The most likely
explanation is that our whole study cohort consisted of patients with
symptomatic atherosclerotic disease. Compared with controls, patients
with vascular disease are generally found to be more vulnerable for
modest cognitive decrements [33], possibly obscuring additional effects
of DM. Despite the absence of a difference in cognition relative to the
patients without DM, there was an additional effect of DM on brain
MRI abnormalities, which was independent of vascular risk factors. Al-
though several potential mechanisms (e.g. vascular disturbances, glu-
cose toxicity, and abnormal insulin signaling in the brain) have been
identiﬁed that may contribute to the brain abnormalities in DM2, it is
yet unclear which of these factors are the main causal factors of brain
abnormalities in humans [2].
Probably brain MRI measures are more sensitive than cognitive
dysfunction to detect differences between patients with and without
DM and may precede differences in cognitive decline. Progression of
brain atrophy and vascular brain lesions seems to be a linear process,
whereas decline in cognition is probably not linear but stepwise. Ac-
cording to the cognitive reserve capacity, a critical threshold should
be reached before clinically relevant deﬁcits emerge [34]. High vascu-
lar burden will lower the threshold, but additional presence of DM
does not increase this process.
Strengths of this study are the prospective design and the large
number of patients investigated with brain MRI and in the majority of
cases also with a neuropsychological assessment. The volumetric as-
sessment of brain atrophy and WMLs made it possible to investigate
the associations on a continuous scale, without loss of information
due to categorization of data. Our automated method is less inﬂuencedby observer bias than visual ratingmethods and enabled us to accurate-
ly measureWMLs and brain volumes. The large scale of the study limit-
ed us to extend the neuropsychological assessment with measures of
cognitive decline on other domains besides memory and executive
functioning. Furthermore, as in many other follow-up studies of aging,
a limitation of this study is that individuals who participated in the
follow-up examination represented a relatively healthy group. The se-
lective loss to follow-up may have led to an underestimation of the ef-
fects. Also, the duration of DM was unknown and we were not able to
distinguish between type 1 and type 2 DM. However, considering the
mean age of the population, it seems plausible that most DM patients
had type 2 DM.
To summarize, in this prospective study we have shown that the
presence of DM on top of existing symptomatic atherosclerotic dis-
ease is associated with increased brain atrophy and vascular brain le-
sion load, at a rate that only slightly exceeds that of patients without
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